drugset / Trial / NCT07229157

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

NCT07229157

Phase 1 Active not recruiting 81 enrolled Amgen
RandomizedCrossoverDouble-blindBasic science

Summary

The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.

Timeline

Start
2025-10-22
Primary completion
2026-08-26
Completion
2026-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Maridebart Cafraglutide Unknown Subcutaneous
Subject Moxifloxacin Small molecule Oral

Indications